Showing 5511-5520 of 8624 results for "".
- ISDIN: Broad Spectrum Sun Protection Cream with DNA Repair Beneficial Post AK Treatmenthttps://practicaldermatology.com/news/isdin-broad-spectrum-sun-protection-cream-with-dna-repair-beneficial-post-ak-treatment/2458319/ISDIN has reported promising results of a 9-month, randomized, investigator-blinded parallel-group study in a poster presentation at the Winter Clinical Conference. The study was designed to evaluate clinical effects of a high SPF film-forming emulsion co
- Encore Dermatology Inc. Launches TridesilonTM (desonide) Cream, 0.05% for ADhttps://practicaldermatology.com/news/encore-dermatology-inc-launches-tridesilontm-desonide-cream-005-for-ad/2458318/Encore Dermatology Inc. is rolling out TridesilonTM (desonide) Cream, 0.05% in a 60g tube for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Encore Dermatology Inc. licensed Tride
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- Non-heterosexual Black Male Teens Use Tanning Beds as Much as Caucasian Female Teenshttps://practicaldermatology.com/news/non-heterosexual-black-male-teens-use-tanning-besds-as-much-as-caucasian-female-teens/2458324/The use of indoor tanning among non-heterosexual black male teens is nearly equal to that of heterosexual white females, according to a study in JAMA Dermatology. The data comes from the 2
- La Roche-Posay and George Washington University Publish International Study on Sun Protection Behavior and Skin Cancer Awarenesshttps://practicaldermatology.com/news/la-roche-posay-and-george-washington-university-publish-international-study-on-sun-protection-behavior-and-skin-cancer-awareness/2458327/A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographical inequalities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need
- Smart Hairbrush and Overachieving Mirrors Make Waves at CES 2017https://practicaldermatology.com/news/smart-hairbrush-and-overachieving-mirrors-make-waves-at-ces-2017/2458328/Beauty is getting a whole lot smarter, and more and more companies are getting in on the game. These are among the main takeaways from the BeautyTech Summit at the annual Consumer Electronics Show (CES), taking place in Las Vegas from Jan. 5-8, 2017. This is the be-all, end-all trade show
- New Compound May Block Spread of Melanoma, Treat Sclerodermahttps://practicaldermatology.com/news/new-compound-may-block-spread-of-melanoma-treat-scleroderma/2458329/A chemical compound, and potential new drug, may reduce the spread of melanoma cells by up to 90 percent, report researchers from Michigan State University in East Lansing. The man-made, small-molecule drug compound goes after a gene’s ability to produce RNA molecules and certain pr
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acnehttps://practicaldermatology.com/news/enrollment-complete-in-biopharmx-phase-2b-study-of-topical-minocycline-gel/2458331/BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, dou
- Provectus Biopharmaceuticals Terminates CEO and COOhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-terminates-ceo-and-coo/2458335/Provectus Biopharmaceuticals, Inc.'s Board of Directors unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the company, including Chief Executive Officer and Chief Operating Officer, for cause in accordance with the terms of his employment a